Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Flowchart of literature search.

More »

Fig 1 Expand

Table 1.

Baseline characteristics of studies in meta-analysis comparing high TMB group with low TMB group in NSCLC patients receiving immunotherapy.

More »

Table 1 Expand

Table 2.

Baseline characteristics of studies in meta-analysis comparing immunotherapy with chemotherapy in NSCLC patients with high or low TMB.

More »

Table 2 Expand

Fig 2.

Forest plot for PFS of high-TMB versus low-TMB in NSCLC patients receiving immunotherapy.

PFS: Progression-free survival; TMB: Tumor mutational burden; NSCLC: Non-small cell lung cancer.

More »

Fig 2 Expand

Table 3.

Subgroup analysis of immunotherapy efficacy for NSCLC in high TMB group versus low TMB group.

More »

Table 3 Expand

Fig 3.

Forest plot for OS of high-TMB versus low-TMB in NSCLC patients receiving immunotherapy.

OS: Overall survival; TMB: Tumor mutational burden; NSCLC: Non-small cell lung cancer.

More »

Fig 3 Expand

Fig 4.

Forest plot for ORR of high-TMB versus low-TMB in NSCLC patients receiving immunotherapy.

OR: Objective response rate; TMB: Tumor mutational burden; NSCLC: Non-small cell lung cancer; OR: Odds ratio.

More »

Fig 4 Expand

Fig 5.

Forest plots of meta-analysis of immunotherapy versus chemotherapy in NSCLC patients with high or low TMB.

(A) PFS in high-TMB patients; (B) PFS in low-TMB patients; (C) OS in high-TMB patients; (D) OS in low-TMB patients; (E) ORR in high-TMB patients; (F) ORR in low-TMB patients.

More »

Fig 5 Expand